Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CLOZAPINE - EFFICACY AND SAFETY
Autore:
BUCHANAN RW;
Indirizzi:
MARYLAND PSYCHIAT RES CTR,OUTPATIENT PROGRAM,POB 21247 BALTIMORE MD 21228 UNIV MARYLAND,SCH MED BALTIMORE MD 21201
Titolo Testata:
Schizophrenia bulletin
fascicolo: 4, volume: 21, anno: 1995,
pagine: 579 - 591
SICI:
0586-7614(1995)21:4<579:C-EAS>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
NEUROLEPTIC MALIGNANT SYNDROME; OBSESSIVE-COMPULSIVE SYMPTOMS; INDUCED WEIGHT-GAIN; TARDIVE-DYSKINESIA; SCHIZOPHRENIC-PATIENTS; CEREBROSPINAL-FLUID; EPILEPTIC SEIZURES; CHLORPROMAZINE; WITHDRAWAL; PSYCHOSIS;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Physical, Chemical & Earth Sciences
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
88
Recensione:
Indirizzi per estratti:
Citazione:
R.W. Buchanan, "CLOZAPINE - EFFICACY AND SAFETY", Schizophrenia bulletin, 21(4), 1995, pp. 579-591

Abstract

Clozapine (Clozaril) represents the first major advance in the pharmacological treatment of schizophrenia since the introduction of antipsychotics into clinical practice in the 1950s. Studies consistently support its efficacy for reducing positive symptoms in acutely psychotic patients and in treatment-resistant patients, for preventing positive symptom exacerbations as a maintenance treatment, and for reducing symptoms of hostility and violence. There is evidence to suggest that clozapine may improve social and occupational functioning and quality of life and may reduce affective symptoms, hospitalizations, secondary negative symptoms, and tardive dyskinesia. Its most significant side effects include agranulocytosis, seizures, weight gain, hypotension and tachycardia, sedation, and perhaps rebound psychosis (with abrupt discontinuation of medication).

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 19:23:17